1. Market Research
  2. > Elan Corporation, plc – Product Pipeline Review – 2013

Elan Corporation, plc – Product Pipeline Review – 2013

  • April 2013
  • -
  • Global Markets Direct
  • -
  • 94 pages

Elan Corporation, plc – Product Pipeline Review – 2013

Summary

Global Market Direct’s pharmaceuticals report, “Elan Corporation, plc - Product Pipeline Review - 2013” provides data on the Elan Corporation, plc’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Elan Corporation, plc’s corporate website, SEC filings, investor presentations and featured press releases, both from Elan Corporation, plc and industry-specific third party sources, put together by Global Markets Direct’s team.

Scope

- Elan Corporation, plc - Brief Elan Corporation, plc overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Elan Corporation, plc human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Elan Corporation, plc with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Elan Corporation, plc’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.

Reasons to buy

- Evaluate Elan Corporation, plc’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Elan Corporation, plc in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Elan Corporation, plc’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Elan Corporation, plc.
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Elan Corporation, plc and identify potential opportunities in those areas.

Table Of Contents

Elan Corporation, plc - Product Pipeline Review - 2013
Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 6
Elan Corporation, plc Snapshot 7
Elan Corporation, plc Overview 7
Key Information 7
Key Facts 7
Elan Corporation, plc - Research and Development Overview 8
Key Therapeutic Areas 8
Elan Corporation, plc - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Combination Treatment Modalities 12
Elan Corporation, plc - Pipeline Products Glance 13
Elan Corporation, plc - Late Stage Pipeline 13
Phase III Products/Combination Treatment Modalities 13
Elan Corporation, plc Clinical Stage Pipeline Products 14
Phase II Products/Combination Treatment Modalities 14
Phase I Products/Combination Treatment Modalities 15
Elan Corporation, plc - Early Stage Pipeline Products 16
Pre-Clinical Products/Combination Treatment Modalities 16
Discovery Products/Combination Treatment Modalities 17
Elan Corporation, plc - Drug Profiles 18
Autoimmune Research 18
Product Description 18
Mechanism of Action 18
RandD Progress 18
Beta Secretase Research 19
Product Description 19
Mechanism of Action 19
RandD Progress 19
ELND-005 20
Product Description 20
Mechanism of Action 20
RandD Progress 20
ELND-005+ [lamotrigine]+ [valproic acid] 22
Product Description 22
Mechanism of Action 22
RandD Progress 22
Gamma Secretase Research 24
Product Description 24
Mechanism of Action 24
RandD Progress 24
natalizumab 25
Product Description 25
Mechanism of Action 25
RandD Progress 25
natalizumab SC 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
Onclave Research Program 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
Parkinson's Research 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
Elan Corporation, plc - Pipeline Analysis 30
Elan Corporation, plc - Pipeline Products by Therapeutic Class 30
Elan Corporation, plc - Pipeline Products by Route of Administration 31
Elan Corporation, plc - Pipeline Products By Mechanism of Action 32
Elan Corporation, plc - Recent Pipeline Updates 34
Elan Corporation, plc - Dormant Projects 39
Elan Corporation, plc - Discontinued Pipeline Products 40
Discontinued Pipeline Product Profiles 40
ELND-002 40
ELND-006 40
ELND-007 40
Elan Corporation, plc - Company Statement 41
Elan Corporation, plc - Locations And Subsidiaries 42
Head Office 42
Other Locations and Subsidiaries 42
Elan Corporation, plc - Key Manufacturing Facilities 43
Elan Corporation, plc, Recent Developments 44
Elan Corporation, plc- Press Release 44
Mar 18, 2013: Biogen Idec and Elan Announce New Tysabri Data Reaffirms Substantial Efficacy In Treatment Of People With MS And Demonstrate Stability Of Anti-JCV Antibody Status 44
Mar 08, 2013: Elan Provides Update On Tysabri Transaction 46
Jan 15, 2013: Biogen Idec And Elan Submit Applications For First-Line Use Of Tysabri In Anti-JCV Antibody Negative Patients With Multiple Sclerosis 46
Dec 22, 2010: Biogen And Elan Submit Applications To Update TYSABRI Labeling 47
Aug 09, 2010: Elan And Transition Announce Topline Results From Phase II Study Of ELND005 For Alzheimer's Disease 48
Apr 16, 2010: Patient-Reported Outcomes Study Shows Improvements In Quality of Life Among Patients After One Year Of Treatment With Tysarbi 49
Apr 13, 2010: Biogen Idec, Elan Present Data On TYSABRI At Annual Meeting Of American Academy Of Neurology 50
Mar 25, 2010: Biogen Idec and Elan Enroll First Patient In Head-to-Head Study Of MS Treatments 51
Financial Deals Landscape 53
Elan Corporation, plc, Deals Summary 53
Elan Corporation, plc, Pharmaceuticals and Healthcare, Deal Details 55
Partnerships 55
University of Cambridge Enters Into Joint Venture Agreement With Elan 55
Proteostasis Therapeutics Enters Into Co-Development Agreement With Elan 57
Elan Enters Into Collaboration With Pharma Product Development 59
Elan Corporation Enters Into Co-Development Agreement With Boehringer Ingelheim 61
Elan Corporation Amends Its Collaboration With Transition Therapeutics 63
PharmatrophiX Enters Into Co-Development Agreement With Elan 64
Circ Pharma Enters Into Co-Development Agreement With Elan 65
Graffinity Pharma Enters Into Research Agreement With Elan 66
Azur Pharma Enters Into Co-Development Agreement With Elan 67
Licensing Agreements 68
Paladin Labs Enters Into Licensing Agreement With Elan For Hydrocodone 68
Intellect Neurosciences Enters Into Licensing Agreement With Wyeth And Elan 69
Ariadne Enters Into Licensing Agreement With Elan Pharma 71
Zogenix Enters Into Licensing Agreement With Elan 72
GeneGo Enters Into Licensing Agreement With Elan Pharma 73
Amarin Enters Into Licensing Agreement With Elan 74
Nitromed Enters Into Licensing Agreement With Elan Pharma 77
Equity Offering 78
Elan Files Registration Statement For Public Offering Of Units For $37.5 Million 78
Elan Completes Private Placement Of $885 Million 79
Debt Offering 81
Elan Completes Public Offering Of Notes Due 2019 For $600 Million 81
Elan Corporation Completes Private Placement Of 8.75% Senior Notes Due 2016 For $200 Million 83
Elan Corporation Completes Private Placement Of Senior Notes For $625 Million 85
Elan Completes Public Offering Senior Floating Rate Notes For $300 Million 86
Asset Transactions 87
Biogen Idec Completes Acquisition Of Tysabri From Elan 87
Azur Pharma Acquires PRIALT From Elan Pharma 90
Johnson and Johnson Acquires Assets And Rights To Alzheimer's Immunotherapy Program From Elan 91
Appendix 93
Methodology 93
Coverage 93
Secondary Research 93
Primary Research 93
Expert Panel Validation 93
Contact Us 94
Disclaimer 94



List of Tables

Elan Corporation, plc, Key Information 7
Elan Corporation, plc, Key Facts 7
Elan Corporation, plc - Pipeline by Indication, 2013 9
Elan Corporation, plc - Pipeline by Stage of Development, 2013 10
Elan Corporation, plc - Monotherapy Products in Pipeline, 2013 11
Elan Corporation, plc - Combination Treatment Modalities in Pipeline, 2013 12
Elan Corporation, plc - Phase III, 2013 13
Elan Corporation, plc - Phase II, 2013 14
Elan Corporation, plc - Phase I, 2013 15
Elan Corporation, plc - Pre-Clinical, 2013 16
Elan Corporation, plc - Discovery, 2013 17
Elan Corporation, plc - Pipeline By Therapeutic Class, 2013 30
Elan Corporation, plc - Pipeline By Route of Administration, 2013 31
Elan Corporation, plc - Pipeline Products By Mechanism of Action, 2013 33
Elan Corporation, plc - Recent Pipeline Updates, 2013 34
Elan Corporation, plc - Dormant Developmental Projects,2013 39
Elan Corporation, plc - Discontinued Pipeline Products, 2013 40
Elan Corporation, plc, Subsidiaries 42
Elan Corporation, plc, Key Manufacturing Facilities 43
Elan Corporation, plc, Deals Summary 53
University of Cambridge Enters Into Joint Venture Agreement With Elan 55
Proteostasis Therapeutics Enters Into Co-Development Agreement With Elan 57
Elan Enters Into Collaboration With Pharma Product Development 59
Elan Corporation Enters Into Co-Development Agreement With Boehringer Ingelheim 61
Elan Corporation Amends Its Collaboration With Transition Therapeutics 63
PharmatrophiX Enters Into Co-Development Agreement With Elan 64
Circ Pharma Enters Into Co-Development Agreement With Elan 65
Graffinity Pharma Enters Into Research Agreement With Elan 66
Azur Pharma Enters Into Co-Development Agreement With Elan 67
Paladin Labs Enters Into Licensing Agreement With Elan For Hydrocodone 68
Intellect Neurosciences Enters Into Licensing Agreement With Wyeth And Elan 69
Ariadne Enters Into Licensing Agreement With Elan Pharma 71
Zogenix Enters Into Licensing Agreement With Elan 72
GeneGo Enters Into Licensing Agreement With Elan Pharma 73
Amarin Enters Into Licensing Agreement With Elan 74
Nitromed Enters Into Licensing Agreement With Elan Pharma 77
Elan Files Registration Statement For Public Offering Of Units For $37.5 Million 78
Elan Completes Private Placement Of $885 Million 79
Elan Completes Public Offering Of Notes Due 2019 For $600 Million 81
Elan Corporation Completes Private Placement Of 8.75% Senior Notes Due 2016 For $200 Million 83
Elan Corporation Completes Private Placement Of Senior Notes For $625 Million 85
Elan Completes Public Offering Senior Floating Rate Notes For $300 Million 86
Biogen Idec Completes Acquisition Of Tysabri From Elan 87
Azur Pharma Acquires PRIALT From Elan Pharma 90
Johnson and Johnson Acquires Assets And Rights To Alzheimer's Immunotherapy Program From Elan 91



List of Figures

Elan Corporation, plc - Pipeline by Indication, 2013 9
Elan Corporation, plc - Pipeline by Stage of Development, 2013 10
Elan Corporation, plc - Monotherapy Products in Pipeline, 2013 11
Elan Corporation, plc - Combination Treatment Modalities in Pipeline, 2013 12
Elan Corporation, plc - Pipeline By Route of Administration, 2013 31
Elan Corporation, plc - Pipeline Products By Mechanism of Action, 2013 32

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.